Giant Biogene Holding Co., Ltd.
HKSE 2367.HK
Giant Biogene Holding Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 47.24%
Giant Biogene Holding Co., Ltd. Operating Income Margin is 47.24% for the year ending December 31, 2023, a -5.87% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
-
Giant Biogene Holding Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 50.19%, a -14.81% change year over year.
-
Giant Biogene Holding Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 58.91%, a 7.59% change year over year.
-
Giant Biogene Holding Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 54.75%, a -23.94% change year over year.
-
Giant Biogene Holding Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 71.98%.
Key data
| Date | Operating Income Margin | EBT Margin | Net Income Margin | EBITDA Margin |
|---|
Market news
Loading...
Don’t Miss A Beat
HKSE: 2367.HK
| CEO | Mr. Jianya Yan |
| IPO Date | Nov. 4, 2022 |
| Location | China |
| Headquarters | No. 1855, Shanglin Yuan |
| Employees | 1,512 |
| Sector | Consumers Staples |
| Industries | |
Description
Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.
Key trends
Past 5 years
StockViz Staff
February 8, 2025
Any question? Send us an email